CELZ
Price
$3.73
Change
+$0.22 (+6.27%)
Updated
Aug 7 closing price
Capitalization
9.06M
RARE
Price
$27.83
Change
-$0.22 (-0.78%)
Updated
Aug 7 closing price
Capitalization
2.68B
88 days until earnings call
Interact to see
Advertisement

CELZ vs RARE

Header iconCELZ vs RARE Comparison
Open Charts CELZ vs RAREBanner chart's image
Creative Medical Technology Holdings
Price$3.73
Change+$0.22 (+6.27%)
Volume$215.49K
Capitalization9.06M
Ultragenyx Pharmaceutical
Price$27.83
Change-$0.22 (-0.78%)
Volume$1.88M
Capitalization2.68B
CELZ vs RARE Comparison Chart in %
Loading...
CELZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CELZ vs. RARE commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELZ is a StrongBuy and RARE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (CELZ: $3.73 vs. RARE: $27.83)
Brand notoriety: CELZ and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELZ: 136% vs. RARE: 88%
Market capitalization -- CELZ: $9.06M vs. RARE: $2.68B
CELZ [@Biotechnology] is valued at $9.06M. RARE’s [@Biotechnology] market capitalization is $2.68B. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELZ’s FA Score shows that 0 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • CELZ’s FA Score: 0 green, 5 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, CELZ is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELZ’s TA Score shows that 4 TA indicator(s) are bullish while RARE’s TA Score has 4 bullish TA indicator(s).

  • CELZ’s TA Score: 4 bullish, 4 bearish.
  • RARE’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CELZ is a better buy in the short-term than RARE.

Price Growth

CELZ (@Biotechnology) experienced а +34.17% price change this week, while RARE (@Biotechnology) price change was +1.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.18%. For the same industry, the average monthly price growth was +8.39%, and the average quarterly price growth was +12.02%.

Reported Earning Dates

RARE is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Biotechnology (+1.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($2.68B) has a higher market cap than CELZ($9.06M). CELZ YTD gains are higher at: 61.472 vs. RARE (-33.848). CELZ has higher annual earnings (EBITDA): -6.17M vs. RARE (-449.9M). RARE has more cash in the bank: 494M vs. CELZ (7.7M). CELZ has less debt than RARE: CELZ (2.74M) vs RARE (38.3M). RARE has higher revenues than CELZ: RARE (591M) vs CELZ (14K).
CELZRARECELZ / RARE
Capitalization9.06M2.68B0%
EBITDA-6.17M-449.9M1%
Gain YTD61.472-33.848-182%
P/E RatioN/AN/A-
Revenue14K591M0%
Total Cash7.7M494M2%
Total Debt2.74M38.3M7%
FUNDAMENTALS RATINGS
CELZ vs RARE: Fundamental Ratings
CELZ
RARE
OUTLOOK RATING
1..100
225
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
3993
P/E GROWTH RATING
1..100
63100
SEASONALITY SCORE
1..100
5036

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CELZ's Valuation (69) in the null industry is in the same range as RARE (74) in the Biotechnology industry. This means that CELZ’s stock grew similarly to RARE’s over the last 12 months.

CELZ's Profit vs Risk Rating (100) in the null industry is in the same range as RARE (100) in the Biotechnology industry. This means that CELZ’s stock grew similarly to RARE’s over the last 12 months.

CELZ's SMR Rating (98) in the null industry is in the same range as RARE (100) in the Biotechnology industry. This means that CELZ’s stock grew similarly to RARE’s over the last 12 months.

CELZ's Price Growth Rating (39) in the null industry is somewhat better than the same rating for RARE (93) in the Biotechnology industry. This means that CELZ’s stock grew somewhat faster than RARE’s over the last 12 months.

CELZ's P/E Growth Rating (63) in the null industry is somewhat better than the same rating for RARE (100) in the Biotechnology industry. This means that CELZ’s stock grew somewhat faster than RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CELZRARE
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
70%
Momentum
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
75%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 1 day ago
80%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 1 day ago
68%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CELZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WMG31.151.11
+3.70%
Warner Music Group Corp
MTRN109.14N/A
N/A
Materion Corp
CYCN2.38-0.01
-0.42%
Cyclerion Therapeutics
MGTX7.65-0.30
-3.77%
MeiraGTx Holdings plc
IKT1.55-0.18
-10.40%
Inhibikase Therapeutics

CELZ and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELZ has been loosely correlated with LABFF. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if CELZ jumps, then LABFF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELZ
1D Price
Change %
CELZ100%
+6.27%
LABFF - CELZ
35%
Loosely correlated
N/A
RARE - CELZ
31%
Poorly correlated
-0.78%
MREO - CELZ
30%
Poorly correlated
-0.63%
WVE - CELZ
30%
Poorly correlated
-5.03%
CRSP - CELZ
29%
Poorly correlated
-0.67%
More